cp-870893
mAbexperimental
Clinical trial activity
8 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2004 (NCT02225002)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109477 ↗
Also known as
- cp 870,893
- cp-870893
- cp-870893
- cp-870,893
- cp-870,893
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01808469 | Phase 1 | Nov 1, 2012 | Leiden University, NovImmune SA |
| NCT01456585 | Phase 1 | Apr 1, 2012 | University of Pennsylvania |
| NCT01103635 | Phase 1 | Feb 1, 2010 | University of Pennsylvania |
| NCT01008527 | Phase 1 | Oct 1, 2009 | National Cancer Institute (NCI), Oncovir, Inc., Pfizer, University of South Florida |
| NCT00711191 | Phase 1 | Jun 1, 2008 | Pfizer, Roche, University of Pennsylvania |
| NCT00607048 | Phase 1 | Nov 1, 2007 | Pfizer, Roche |
| NCT02157831 | Early Phase 1 (Phase 1) | Jul 1, 2005 | University of Pennsylvania |
| NCT02225002 | Phase 1 | Jan 1, 2004 | University of Pennsylvania |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Pennsylvania | Academic/Hospital | 5 | 4 | 1 | 2004 |
| Pfizer | For profit | 3 | 0 | 1 | 2007 |
| Roche | For profit | 2 | 2 | 1 | 2007 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2012 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2009 |
| NovImmune SA | For profit | 1 | 1 | 1 | 2012 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2009 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2009 |
8 organizations
Page 1 / 1